Education
About Us
Working with TipRanks
Follow Us
PetVivo Holdings (PETV)
OTHER OTC:PETV
PETV Stock Chart & Stats
$1.12
$0.00(0.00%)
At close: 4:00 PM EST
$1.12
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.45 - $1.69
Previous CloseN/A
Volume249.00
Average Volume (3M)21.60K
Market Cap
$27.31M
Enterprise Value$21.20M
Total Cash (Recent Filing)$168.16K
Total Debt (Recent Filing)$70.56K
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Jun 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding35,017,418
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.91
Price to Sales (P/S)10.86
P/FCF Ratio-2.09
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue19.07
Enterprise Value/Gross Profit28.88
Enterprise Value/Ebitda-2.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Exclusive AI SaaS LicenseThe 10-year exclusive white-label license and PetVivo AI SaaS launch create a structurally recurring, high-margin revenue stream. Over time this diversifies revenue away from one-off device sales, leverages low CapEx for scaling, and can materially improve unit economics if adoption and renewals hold.
Distribution PartnershipsCommitments from VGP and international distributors materially expand PetVivo’s go-to-market reach. Durable channel access reduces customer-acquisition friction, accelerates clinical adoption of Spryng and PrecisePRP, and supports a multi-quarter revenue base that can feed both product and subscription growth.
Low Leverage & Gross MarginsVery low leverage combined with solid gross margins provides balance-sheet flexibility and margin resilience during commercialization. Low debt reduces refinancing risk while a ~66% gross margin means incremental sales can flow more directly to covering fixed costs as revenue scales, improving long-term profitability prospects.
Bears Say
Sustained Cash BurnPersistently negative operating and free cash flow indicates the company must rely on external financing to fund operations and commercialization. Ongoing burn limits runway, raises dilution risk, and constrains ability to invest in sales, R&D, or marketing until recurring SaaS or product revenues scale sustainably.
Deep Unprofitability & Revenue PressureA steep decline in revenue coupled with outsized operating and net losses undermines capital stability. Negative returns on equity and shrinking equity raise the probability of further dilutive financings; without material margin improvement or meaningful recurring revenue, long-term viability remains uncertain.
AI Timing And Guidance UncertaintyManagement’s AI monetization timetable remains directional rather than confirmed, and no quantitative guidance was given. The business therefore faces execution and timing risk: planned high-margin SaaS revenue must materialize to offset product losses, and any delay increases financing and operational pressure.
PetVivo Holdings News
PETV FAQ
What was PetVivo Holdings’s price range in the past 12 months?
PetVivo Holdings lowest stock price was $0.45 and its highest was $1.69 in the past 12 months.
What is PetVivo Holdings’s market cap?
PetVivo Holdings’s market cap is $27.31M.
When is PetVivo Holdings’s upcoming earnings report date?
PetVivo Holdings’s upcoming earnings report date is Jun 25, 2026 which is in 111 days.
How were PetVivo Holdings’s earnings last quarter?
PetVivo Holdings released its earnings results on Feb 17, 2026. The company reported -$0.069 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.069.
Is PetVivo Holdings overvalued?
According to Wall Street analysts PetVivo Holdings’s price is currently Overvalued.
Does PetVivo Holdings pay dividends?
PetVivo Holdings does not currently pay dividends.
What is PetVivo Holdings’s EPS estimate?
PetVivo Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PetVivo Holdings have?
PetVivo Holdings has 35,017,418 shares outstanding.
What happened to PetVivo Holdings’s price movement after its last earnings report?
PetVivo Holdings reported an EPS of -$0.069 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.881%.
Which hedge fund is a major shareholder of PetVivo Holdings?
Currently, no hedge funds are holding shares in PETV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PetVivo Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.25%
12-Months-Change
Fundamentals
Return on Equity
-379.92%
Trailing 12-Months
Asset Growth
138.51%
Trailing 12-Months
Company Description
PetVivo Holdings
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
PETV Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive strategic and operational narrative: management secured transformative partnerships (exclusive AI licensing, major distributor and channel agreements), advanced R&D and international commercialization (Health Canada recognition, U.K. and Mexico distribution), and materially reduced liabilities (≈81% decline). These developments position the company for a recurring, high-margin SaaS revenue stream (PetVivo AI) that could complement device and biologic sales. Near-term financials remain challenging — modest revenue decline (−2% YoY for nine months), lower gross margins from product mix, ongoing operating losses (net loss $7.5M) and cash burn ($5.3M) leave liquidity and timing risks. Overall, the strategic progress and balance sheet improvements outweigh the current financial headwinds, suggesting a Positive sentiment with execution and monetization of AI and commercialization plans as key drivers to watch.View all PETV earnings summariesTechnical Analysis
Iridex
―
Lifeward
―
Vivos Therapeutics
―
Allurion Technologies
―
Nexalin Technology, Inc.
―
Ownership Overview
34.52% Insiders
0.38% Other Institutional Investors
65.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---